BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Antonangeli F, Natalini A, Garassino MC, Sica A, Santoni A, Di Rosa F. Regulation of PD-L1 Expression by NF-κB in Cancer. Front Immunol 2020;11:584626. [PMID: 33324403 DOI: 10.3389/fimmu.2020.584626] [Cited by in Crossref: 76] [Cited by in F6Publishing: 81] [Article Influence: 38.0] [Reference Citation Analysis]
Number Citing Articles
1 Li Z, Kim H, Kim J, Park JH. EP400NL is involved in PD-L1 gene activation by forming a transcriptional coactivator complex. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 2023;1866:194889. [DOI: 10.1016/j.bbagrm.2022.194889] [Reference Citation Analysis]
2 Liu L, Lei Y, Chen W, Zhou Q, Zheng Z, Zeng G, Liu W, Feng P, Zhang Z, Yu L, Chen L. In vivo genome-wide CRISPR screening identifies ZNF24 as a negative NF-κB modulator in lung cancer. Cell Biosci 2022;12:193. [PMID: 36457047 DOI: 10.1186/s13578-022-00933-0] [Reference Citation Analysis]
3 Peng M, Fan S, Li J, Zhou X, Liao Q, Tang F, Liu W. Programmed death-ligand 1 signaling and expression are reversible by lycopene via PI3K/AKT and Raf/MEK/ERK pathways in tongue squamous cell carcinoma. Genes Nutr 2022;17:3. [DOI: 10.1186/s12263-022-00705-y] [Reference Citation Analysis]
4 Vlachostergios PJ, Tamposis IA, Anagnostou M, Papathanassiou M, Mitrakas L, Zachos I, Thodou E, Samara M, Tzortzis V. Hypoxia-Inducible Factor-2-Altered Urothelial Carcinoma: Clinical and Genomic Features. Current Oncology 2022;29:8638-8649. [DOI: 10.3390/curroncol29110681] [Reference Citation Analysis]
5 Karizak AZ, Salmasi Z, Gheibihayat SM, Asadi M, Ghasemi Y, Tajbakhsh A, Savardashtaki A. Understanding the regulation of “Don’t Eat-Me” signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy. J Cancer Res Clin Oncol 2022. [DOI: 10.1007/s00432-022-04452-w] [Reference Citation Analysis]
6 Kwon M, Jung J, Park HS, Kim NH, Lee J, Park J, Kim Y, Shin S, Lee BS, Cheong YH, Youn H, Kim SR, Park S. Diesel exhaust particle exposure accelerates oxidative DNA damage and cytotoxicity in normal human bronchial epithelial cells through PD-L1. Environmental Pollution 2022. [DOI: 10.1016/j.envpol.2022.120705] [Reference Citation Analysis]
7 Yang Q, Liu T, zheng H, Zhou Z, Huang Y, Jia H, Fu S, Zhang X, Zhang H, Liu Y, Chen X, Shan W. A nanoformulation for immunosuppression reversal and broad-spectrum self-amplifying antitumor ferroptosis-immunotherapy. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121936] [Reference Citation Analysis]
8 Chow CY, Lie EF, Wu C, Chow LW. Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.964824] [Reference Citation Analysis]
9 Lin D, Xu W, Hong P, Wu C, Zhang Z, Zhang S, Xing L, Yang B, Zhou W, Xiao Q, Wang J, Wang C, He Y, Chen X, Cao X, Man J, Reheman A, Wu X, Hao X, Hu Z, Chen C, Cao Z, Yin R, Fu ZF, Zhou R, Teng Z, Li G, Cao G. Decoding the spatial chromatin organization and dynamic epigenetic landscapes of macrophage cells during differentiation and immune activation. Nat Commun 2022;13:5857. [PMID: 36195603 DOI: 10.1038/s41467-022-33558-5] [Reference Citation Analysis]
10 Quan Z, Yang Y, Zheng H, Zhan Y, Luo J, Ning Y, Fan S. Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer. J Cancer 2022;13:3434-43. [PMID: 36313041 DOI: 10.7150/jca.77619] [Reference Citation Analysis]
11 Liu K, Sun Q, Liu Q, Li H, Zhang W, Sun C. Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy. Biomedicine & Pharmacotherapy 2022;154:113618. [DOI: 10.1016/j.biopha.2022.113618] [Reference Citation Analysis]
12 Fang L, Liu K, Liu C, Wang X, Ma W, Xu W, Wu J, Sun C. Tumor accomplice: T cell exhaustion induced by chronic inflammation. Front Immunol 2022;13:979116. [DOI: 10.3389/fimmu.2022.979116] [Reference Citation Analysis]
13 Lu J, Fei F, Wu C, Mei J, Xu J, Lu P. ZEB1: Catalyst of immune escape during tumor metastasis. Biomedicine & Pharmacotherapy 2022;153:113490. [DOI: 10.1016/j.biopha.2022.113490] [Reference Citation Analysis]
14 Jardin F. NFkB Pathway and Hodgkin Lymphoma. Biomedicines 2022;10:2153. [DOI: 10.3390/biomedicines10092153] [Reference Citation Analysis]
15 Pan J, Yang H, Zhu L, Lou Y, Jin B. Qingfei Jiedu decoction inhibits PD-L1 expression in lung adenocarcinoma based on network pharmacology analysis, molecular docking and experimental verification. Front Pharmacol 2022;13:897966. [DOI: 10.3389/fphar.2022.897966] [Reference Citation Analysis]
16 Guo D, Tong Y, Jiang X, Meng Y, Jiang H, Du L, Wu Q, Li S, Luo S, Li M, Xiao L, He H, He X, Yu Q, Fang J, Lu Z. Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IκBα. Cell Metab 2022:S1550-4131(22)00345-X. [PMID: 36007522 DOI: 10.1016/j.cmet.2022.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Huang C, Wang N, Zhang N, Chen Z, Ni Z, Liu X, Xiong H, Xie H, Lin B, Ge B, Huang Q, Du B. Multi-omics analysis for potential inflammation-related genes involved in tumour immune evasion via extended application of epigenetic data. Open Biol 2022;12:210375. [PMID: 35946310 DOI: 10.1098/rsob.210375] [Reference Citation Analysis]
18 Erol A. Genotoxicity-Stimulated and CYLD-Driven Malignant Transformation. CMAR 2022;Volume 14:2339-56. [DOI: 10.2147/cmar.s373557] [Reference Citation Analysis]
19 Zafari N, Khosravi F, Rezaee Z, Esfandyari S, Bahiraei M, Bahramy A, Ferns GA, Avan A. The role of the tumor microenvironment in colorectal cancer and the potential therapeutic approaches. J Clin Lab Anal 2022;:e24585. [PMID: 35808903 DOI: 10.1002/jcla.24585] [Reference Citation Analysis]
20 Goldufsky JW, Daniels P, Williams MD, Gupta K, Lyday B, Chen T, Singh G, Zloza A, Marzo AL. Attenuated Dengue Virus PV001-DV Induces Oncolytic Cell Death and Potent Anti-Tumor Immunity.. [DOI: 10.1101/2022.07.05.498884] [Reference Citation Analysis]
21 Lüke F, Harrer DC, Pantziarka P, Pukrop T, Ghibelli L, Gerner C, Reichle A, Heudobler D. Drug Repurposing by Tumor Tissue Editing. Front Oncol 2022;12:900985. [DOI: 10.3389/fonc.2022.900985] [Reference Citation Analysis]
22 Kandala S, von Voithenberg LV, Chocarro S, Ramos M, Keding J, Brors B, Imbusch CD, Sotillo R. Chronic chromosome instability induced by Plk1 results in immune suppression in breast cancer.. [DOI: 10.1101/2022.06.16.496429] [Reference Citation Analysis]
23 Okuyama K, Yanamoto S. TMEM16A as a potential treatment target for head and neck cancer. J Exp Clin Cancer Res 2022;41:196. [PMID: 35668455 DOI: 10.1186/s13046-022-02405-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Zhang Z, Bu L, Luo J, Guo J. Targeting protein kinases benefits cancer immunotherapy. Biochim Biophys Acta Rev Cancer 2022;:188738. [PMID: 35660645 DOI: 10.1016/j.bbcan.2022.188738] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Soltanshahi M, Taghiloo S, Asgarian-omran H. Expression Modulation of Immune Checkpoint Molecules by Ibrutinib and Everolimus Through STAT3 in MCF-7 Breast Cancer Cells. Iran J Pharm Res 2022;21. [DOI: 10.5812/ijpr-127352] [Reference Citation Analysis]
26 Laurin KM, Coutu-Beaudry K, Salazar A, Méribout N, Audet-Walsh É, Gravel SP. Low expression of PGC-1β and other mitochondrial biogenesis modulators in melanoma is associated with growth arrest and the induction of an immunosuppressive gene expression program dependent on MEK and IRF-1. Cancer Lett 2022;:215738. [PMID: 35594996 DOI: 10.1016/j.canlet.2022.215738] [Reference Citation Analysis]
27 Bai R, Cui J. Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy. Front Immunol 2022;13:886931. [DOI: 10.3389/fimmu.2022.886931] [Reference Citation Analysis]
28 Lu T, Zhang Z, Zhang J, Pan X, Zhu X, Wang X, Li Z, Ruan M, Li H, Chen W, Yan M. CD73 in small extracellular vesicles derived from HNSCC defines tumour-associated immunosuppression mediated by macrophages in the microenvironment. J Extracell Vesicles 2022;11:e12218. [PMID: 35524455 DOI: 10.1002/jev2.12218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Li N, Geng F, Liang SM, Qin X. USP7 inhibits TIMP2 by up-regulating the expression of EZH2 to activate the NF-κB/PD-L1 axis to promote the development of cervical cancer. Cell Signal 2022;:110351. [PMID: 35523402 DOI: 10.1016/j.cellsig.2022.110351] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Chen B, Hu J, Hu X, Chen H, Bao R, Zhou Y, Ye Y, Zhan M, Cai W, Li H, Li HB. DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion. Nat Commun 2022;13:2059. [PMID: 35440133 DOI: 10.1038/s41467-022-29754-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Li C, Pan B, Wang X, Liu X, Qin J, Gao T, Sun H, Pan Y, Wang S. Upregulated LINC01088 facilitates malignant phenotypes and immune escape of colorectal cancer by regulating microRNAs/G3BP1/PD-L1 axis. J Cancer Res Clin Oncol 2022. [PMID: 35357586 DOI: 10.1007/s00432-022-03981-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Gao Q, Cui L, Huang C, Zhou C, Chen B, Wang Q, Chen Z, Zhao Y, Wang M, Shen B, Xu W, Zhu W. Gastric cancer-derived exosomes induce PD-L1 expression on human bone marrow mesenchymal stem cells through the AKT-c-Myc signal axis. All Life 2022;15:442-51. [DOI: 10.1080/26895293.2022.2058098] [Reference Citation Analysis]
33 Tang T, Huang X, Zhang G, Lu M, Hong Z, Wang M, Huang J, Zhi X, Liang T. Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis. J Immunother Cancer 2022;10:e004129. [PMID: 35288467 DOI: 10.1136/jitc-2021-004129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Bruns IB, Beltman JB. Quantifying the contribution of transcription factor activity, mutations and microRNAs to CD274 expression in cancer patients. Sci Rep 2022;12:4374. [PMID: 35289334 DOI: 10.1038/s41598-022-08356-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Chen Y, Chen Z, Chen R, Fang C, Zhang C, Ji M, Yang X. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant NSCLC. Future Oncol 2022. [PMID: 35232247 DOI: 10.2217/fon-2021-0862] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Fan Z, Wu C, Chen M, Jiang Y, Wu Y, Mao R, Fan Y. The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation. Acta Pharm Sin B 2022;12:1041-53. [PMID: 35530130 DOI: 10.1016/j.apsb.2021.09.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Zhou J, Li J, Qian C, Qiu F, Shen Q, Tong R, Yang Q, Xu J, Zheng B, Lv J, Hou J. LINC00624/TEX10/NF-κB axis promotes proliferation and migration of human prostate cancer cells. Biochem Biophys Res Commun 2022;601:1-8. [PMID: 35219000 DOI: 10.1016/j.bbrc.2022.02.078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
38 Widjaya AS, Liu Y, Yang Y, Yin W, Liang J, Jiang Y. Tumor-permeable smart liposomes by modulating the tumor microenvironment to improve the chemotherapy. J Control Release 2022:S0168-3659(22)00094-3. [PMID: 35182612 DOI: 10.1016/j.jconrel.2022.02.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
39 Yadav D, Kwak M, Chauhan PS, Puranik N, Lee PCW, Jin JO. Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials. Semin Cancer Biol 2022:S1044-579X(22)00044-X. [PMID: 35181474 DOI: 10.1016/j.semcancer.2022.02.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
40 Shen C, Han L, Liu B, Zhang G, Cai Z, Yin X, Yin Y, Chen Z, Zhang B. The KDM6A-SPARCL1 axis blocks metastasis and regulates the tumour microenvironment of gastrointestinal stromal tumours by inhibiting the nuclear translocation of p65. Br J Cancer 2022. [PMID: 35136209 DOI: 10.1038/s41416-022-01728-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Miao D, Shi J, Xiong Z, Xiao W, Meng X, Lv Q, Xie K, Yang H, Zhang X. As a prognostic biomarker of clear cell renal cell carcinoma RUFY4 predicts immunotherapy responsiveness in a PDL1-related manner. Cancer Cell Int 2022;22:66. [PMID: 35135552 DOI: 10.1186/s12935-022-02480-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Xu R, Liu X, Li A, Song L, Liang J, Gao J, Tang X. c-Met up-regulates the expression of PD-L1 through MAPK/NF-κBp65 pathway. J Mol Med (Berl) 2022. [PMID: 35122106 DOI: 10.1007/s00109-022-02179-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Cristiani CM, Capone M, Garofalo C, Madonna G, Mallardo D, Tuffanelli M, Vanella V, Greco M, Foti DP, Viglietto G, Ascierto PA, Spits H, Carbone E. Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors. Front Immunol 2022;13:811131. [DOI: 10.3389/fimmu.2022.811131] [Reference Citation Analysis]
44 Kaltschmidt B, Witte KE, Greiner JFW, Weissinger F, Kaltschmidt C. Targeting NF-κB Signaling in Cancer Stem Cells: A Narrative Review. Biomedicines 2022;10:261. [PMID: 35203471 DOI: 10.3390/biomedicines10020261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
45 Tanaka Y, Takeda R, Fukushima T, Mikami K, Tsuchiya S, Tamura M, Adachi K, Umemoto T, Asada S, Watanabe N, Morishita S, Imai M, Nagata M, Araki M, Takizawa H, Fukuyama T, Lamagna C, Masuda ES, Ito R, Goyama S, Komatsu N, Takaku T, Kitamura T. Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors. Nat Commun 2022;13:271. [PMID: 35022428 DOI: 10.1038/s41467-021-27928-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
46 Zhang Z, Zhang H, Liu T, Chen T, Wang D, Tang D. Heterogeneous Pancreatic Stellate Cells Are Powerful Contributors to the Malignant Progression of Pancreatic Cancer. Front Cell Dev Biol 2021;9:783617. [PMID: 34988078 DOI: 10.3389/fcell.2021.783617] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
47 Zhang T, Ma C, Zhang Z, Zhang H, Hu H. NF-κB signaling in inflammation and cancer. MedComm (2020) 2021;2:618-53. [PMID: 34977871 DOI: 10.1002/mco2.104] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 20.0] [Reference Citation Analysis]
48 Bedhiafi T, Inchakalody VP, Fernandes Q, Mestiri S, Billa N, Uddin S, Merhi M, Dermime S. The potential role of vitamin C in empowering cancer immunotherapy. Biomed Pharmacother 2021;146:112553. [PMID: 34923342 DOI: 10.1016/j.biopha.2021.112553] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
49 Das D, Karthik N, Taneja R. Crosstalk Between Inflammatory Signaling and Methylation in Cancer. Front Cell Dev Biol 2021;9:756458. [PMID: 34901003 DOI: 10.3389/fcell.2021.756458] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
50 Gitto S, Natalini A, Antonangeli F, Di Rosa F. The Emerging Interplay Between Recirculating and Tissue-Resident Memory T Cells in Cancer Immunity: Lessons Learned From PD-1/PD-L1 Blockade Therapy and Remaining Gaps. Front Immunol 2021;12:755304. [PMID: 34867987 DOI: 10.3389/fimmu.2021.755304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Chun KS, Kim DH, Raut PK, Surh YJ. Anticancer natural products targeting immune checkpoint protein network. Semin Cancer Biol 2021:S1044-579X(21)00279-0. [PMID: 34838956 DOI: 10.1016/j.semcancer.2021.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Kopecka J, Salaroglio IC, Perez-Ruiz E, Sarmento-Ribeiro AB, Saponara S, De Las Rivas J, Riganti C. Hypoxia as a driver of resistance to immunotherapy. Drug Resist Updat 2021;:100787. [PMID: 34840068 DOI: 10.1016/j.drup.2021.100787] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
53 Pucci M, Raimondo S, Urzì O, Moschetti M, Di Bella MA, Conigliaro A, Caccamo N, La Manna MP, Fontana S, Alessandro R. Tumor-Derived Small Extracellular Vesicles Induce Pro-Inflammatory Cytokine Expression and PD-L1 Regulation in M0 Macrophages via IL-6/STAT3 and TLR4 Signaling Pathways. Int J Mol Sci 2021;22:12118. [PMID: 34829995 DOI: 10.3390/ijms222212118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
54 Huang C, Wang N, Zhang N, Ni Z, Liu X, Xiong H, Xie H, Lin B, Ge B, Huang Q, Du B. Multi-omics analysis for potential inflammation-related genes involved in tumor immune evasion via extended application of epigenetic data.. [DOI: 10.1101/2021.11.04.467249] [Reference Citation Analysis]
55 El-Ashmawy NE, Salem ML, Abd El-Fattah EE, Khedr EG. Targeting CD166+ lung cancer stem cells: Molecular study using murine dendritic cell vaccine. Toxicol Appl Pharmacol 2021;429:115699. [PMID: 34437932 DOI: 10.1016/j.taap.2021.115699] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
56 Yang Y, Li N, Wang TM, Di L. Natural Products with Activity against Lung Cancer: A Review Focusing on the Tumor Microenvironment. Int J Mol Sci 2021;22:10827. [PMID: 34639167 DOI: 10.3390/ijms221910827] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
57 Li Y, Ni K, Chan C, Guo N, Luo T, Han W, Culbert A, Weichselbaum RR, Lin W. Dimethylaminomicheliolide Sensitizes Cancer Cells to Radiotherapy for Synergistic Combination with Immune Checkpoint Blockade. Advanced Therapeutics 2022;5:2100160. [DOI: 10.1002/adtp.202100160] [Reference Citation Analysis]
58 El-ashmawy N, Salem M, Abd El-fattah E, Khedr E. Targeting CD166+ lung cancer stem cells: Molecular study using murine dendritic cell vaccine. Toxicology and Applied Pharmacology 2021;429:115699. [DOI: 10.1016/j.taap.2021.115699] [Reference Citation Analysis]
59 Bailly C. Anticancer Targets and Signaling Pathways Activated by Britannin and Related Pseudoguaianolide Sesquiterpene Lactones. Biomedicines 2021;9:1325. [PMID: 34680439 DOI: 10.3390/biomedicines9101325] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
60 Garcia-Lacarte M, Grijalba SC, Melchor J, Arnaiz-Leché A, Roa S. The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas. Cancers (Basel) 2021;13:4683. [PMID: 34572910 DOI: 10.3390/cancers13184683] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Chen W, Gao C, Shen J, Yao L, Liang X, Chen Z. The expression and prognostic value of REXO4 in hepatocellular carcinoma. J Gastrointest Oncol 2021;12:1704-17. [PMID: 34532121 DOI: 10.21037/jgo-21-98] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Yun BD, Son SW, Choi SY, Kuh HJ, Oh TJ, Park JK. Anti-Cancer Activity of Phytochemicals Targeting Hypoxia-Inducible Factor-1 Alpha. Int J Mol Sci 2021;22:9819. [PMID: 34575983 DOI: 10.3390/ijms22189819] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
63 Venet M, Sa Ribeiro M, Décembre E, Bellomo A, Joshi G, Villard M, Cluet D, Perret M, Pescamona R, Paidassi H, Walzer T, Allatif O, Belot A, Assant S, Ricci E, Dreux M. Severe COVID-19 patients have impaired plasmacytoid dendritic cell-mediated control of SARS-CoV-2-infected cells.. [DOI: 10.1101/2021.09.01.21262969] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
64 Delmas D, Hermetet F, Aires V. PD-1/PD-L1 Checkpoints and Resveratrol: A Controversial New Way for a Therapeutic Strategy. Cancers (Basel) 2021;13:4509. [PMID: 34572736 DOI: 10.3390/cancers13184509] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
65 Li Y, Liu H, Zhao Y, Yue D, Chen C, Li C, Zhang Z, Wang C. Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC). Thorac Cancer 2021;12:2698-709. [PMID: 34423566 DOI: 10.1111/1759-7714.14108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
66 Gilmore TD. NF-κB and Human Cancer: What Have We Learned over the Past 35 Years? Biomedicines 2021;9:889. [PMID: 34440093 DOI: 10.3390/biomedicines9080889] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
67 Porcellato I, Mecocci S, Brachelente C, Cappelli K, Armando F, Tognoloni A, Chiaradia E, Stefanetti V, Mechelli L, Pepe M, Gialletti R, Passeri B, Ghelardi A, Razzuoli E. PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas. Animals (Basel) 2021;11:2121. [PMID: 34359249 DOI: 10.3390/ani11072121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
68 Liu S, Liu X, Zhang C, Shan W, Qiu X. T-Cell Exhaustion Status Under High and Low Levels of Hypoxia-Inducible Factor 1α Expression in Glioma. Front Pharmacol 2021;12:711772. [PMID: 34305618 DOI: 10.3389/fphar.2021.711772] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
69 Kang C, Song CH, Kim N, Nam RH, Choi SI, Yu JE, Nho H, Choi JA, Kim JW, Na HY, Lee HN, Surh YJ. The Enhanced Inhibitory Effect of Estrogen on PD-L1 Expression Following Nrf2 Deficiency in the AOM/DSS Model of Colitis-Associated Cancer. Front Oncol 2021;11:679324. [PMID: 34307147 DOI: 10.3389/fonc.2021.679324] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Zouein J, Kesrouani C, Kourie HR. PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare. Immunotherapy 2021;13:1053-65. [PMID: 34190579 DOI: 10.2217/imt-2020-0336] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
71 Shen J, Liu T, Bei Q, Xu S. Comprehensive Landscape of Ovarian Cancer Immune Microenvironment Based on Integrated Multi-Omics Analysis. Front Oncol 2021;11:685065. [PMID: 34222009 DOI: 10.3389/fonc.2021.685065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Antognelli C, Mandarano M, Prosperi E, Sidoni A, Talesa VN. Glyoxalase-1-Dependent Methylglyoxal Depletion Sustains PD-L1 Expression in Metastatic Prostate Cancer Cells: A Novel Mechanism in Cancer Immunosurveillance Escape and a Potential Novel Target to Overcome PD-L1 Blockade Resistance. Cancers (Basel) 2021;13:2965. [PMID: 34199263 DOI: 10.3390/cancers13122965] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
73 Vetrei C, Passariello M, Froechlich G, Rapuano Lembo R, Zambrano N, De Lorenzo C. Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments. Cancers (Basel) 2021;13:2858. [PMID: 34201082 DOI: 10.3390/cancers13122858] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
74 Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, Zeng WJ, Liu Z, Cheng Q. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res 2021;40:184. [PMID: 34088360 DOI: 10.1186/s13046-021-01987-7] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 79.0] [Reference Citation Analysis]
75 Li Z, Fitzsimons HL, Hale TK, Park JH. EP400NL is required for cMyc-mediated PD-L1 gene activation by forming a transcriptional coactivator complex.. [DOI: 10.1101/2021.05.30.446361] [Reference Citation Analysis]
76 Hibino S, Kawazoe T, Kasahara H, Itoh S, Ishimoto T, Sakata-Yanagimoto M, Taniguchi K. Inflammation-Induced Tumorigenesis and Metastasis. Int J Mol Sci 2021;22:5421. [PMID: 34063828 DOI: 10.3390/ijms22115421] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 26.0] [Reference Citation Analysis]
77 Uchihara Y, Permata TBM, Sato H, Shibata A. Modulation of immune responses by DNA damage signaling. DNA Repair (Amst) 2021;104:103135. [PMID: 34029876 DOI: 10.1016/j.dnarep.2021.103135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
78 Oh JY, Lee RH. Mesenchymal stromal cells for the treatment of ocular autoimmune diseases. Prog Retin Eye Res 2021;:100967. [PMID: 33775824 DOI: 10.1016/j.preteyeres.2021.100967] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
79 Song L, Zhu S, Liu C, Zhang Q, Liang X. Baicalin triggers apoptosis, inhibits migration, and enhances anti-tumor immunity in colorectal cancer via TLR4/NF-κB signaling pathway. J Food Biochem 2021;:e13703. [PMID: 33742464 DOI: 10.1111/jfbc.13703] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
80 Lettieri S, Oggionni T, Lancia A, Bortolotto C, Stella GM. Immune Stroma in Lung Cancer and Idiopathic Pulmonary Fibrosis: A Common Biologic Landscape? Int J Mol Sci 2021;22:2882. [PMID: 33809111 DOI: 10.3390/ijms22062882] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
81 Ehrlich M, Bacharach E. Oncolytic Virotherapy: The Cancer Cell Side. Cancers (Basel) 2021;13:939. [PMID: 33668131 DOI: 10.3390/cancers13050939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
82 Cuollo L, Antonangeli F, Santoni A, Soriani A. The Senescence-Associated Secretory Phenotype (SASP) in the Challenging Future of Cancer Therapy and Age-Related Diseases. Biology (Basel) 2020;9:485. [PMID: 33371508 DOI: 10.3390/biology9120485] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 22.0] [Reference Citation Analysis]